503 related articles for article (PubMed ID: 28813519)
1. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
2. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome.
Skotheim RI; Kallioniemi A; Bjerkhagen B; Mertens F; Brekke HR; Monni O; Mousses S; Mandahl N; Soeter G; Nesland JM; Smeland S; Kallioniemi OP; Lothe RA
J Clin Oncol; 2003 Dec; 21(24):4586-91. PubMed ID: 14673046
[TBL] [Abstract][Full Text] [Related]
4. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
6. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
7. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
8. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
9. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
[TBL] [Abstract][Full Text] [Related]
10. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
Kresse SH; Skårn M; Ohnstad HO; Namløs HM; Bjerkehagen B; Myklebost O; Meza-Zepeda LA
Mol Cancer; 2008 Jun; 7():48. PubMed ID: 18522746
[TBL] [Abstract][Full Text] [Related]
11. Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Kartal P; Vriends ALM; French PJ; van Royen ME; Taal W; Sleijfer S; Wiemer EAC
Sci Rep; 2020 Feb; 10(1):2927. PubMed ID: 32076030
[TBL] [Abstract][Full Text] [Related]
12. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer.
Wu X; Liu D; Tao D; Xiang W; Xiao X; Wang M; Wang L; Luo G; Li Y; Zeng F; Jiang G
Mol Cancer Ther; 2016 May; 15(5):1029-42. PubMed ID: 26939702
[TBL] [Abstract][Full Text] [Related]
13. Subclassification of nerve sheath tumors by gene expression profiling.
Holtkamp N; Reuss DE; Atallah I; Kuban RJ; Hartmann C; Mautner VF; Frahm S; Friedrich RE; Algermissen B; Pham VA; Prietz S; Rosenbaum T; Estevez-Schwarz L; von Deimling A
Brain Pathol; 2004 Jul; 14(3):258-64. PubMed ID: 15446580
[TBL] [Abstract][Full Text] [Related]
14. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.
Lévy P; Vidaud D; Leroy K; Laurendeau I; Wechsler J; Bolasco G; Parfait B; Wolkenstein P; Vidaud M; Bièche I
Mol Cancer; 2004 Jul; 3():20. PubMed ID: 15255999
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
[TBL] [Abstract][Full Text] [Related]
18. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.
Holtkamp N; Mautner VF; Friedrich RE; Harder A; Hartmann C; Theallier-Janko A; Hoffmann KT; von Deimling A
Acta Neuropathol; 2004 Feb; 107(2):159-68. PubMed ID: 14673600
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
20. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
[No Abstract] [Full Text] [Related]
[Next] [New Search]